SPIRIVA RESPIMAT Drug Patent Profile

Which patents cover Spiriva Respimat, and what generic alternatives are available?

Spiriva Respimat is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-two patent family members in thirty-five countries.

The generic ingredient in SPIRIVA RESPIMAT is tiotropium bromide. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the tiotropium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Spiriva Respimat

A generic version of SPIRIVA RESPIMAT was approved as tiotropium bromide by LUPIN on June 20^th, 2023.

Summary for SPIRIVA RESPIMAT

International Patents:	72
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	74
Clinical Trials:	27
Patent Applications:	3,938
Drug Prices:	Drug price information for SPIRIVA RESPIMAT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SPIRIVA RESPIMAT
What excipients (inactive ingredients) are in SPIRIVA RESPIMAT?	SPIRIVA RESPIMAT excipients list
DailyMed Link:	SPIRIVA RESPIMAT at DailyMed

See drug prices for SPIRIVA RESPIMAT

Recent Clinical Trials for SPIRIVA RESPIMAT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Saskatchewan	Phase 4
Nemours Children's Clinic	Phase 2
Rho, Inc.	Phase 2

See all SPIRIVA RESPIMAT clinical trials

Pharmacology for SPIRIVA RESPIMAT

Drug Class	Anticholinergic
Mechanism of Action	Cholinergic Antagonists

Paragraph IV (Patent) Challenges for SPIRIVA RESPIMAT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SPIRIVA RESPIMAT	Inhalation Aerosol	tiotropium bromide	2.5 mcg per actuation	021936	1	2023-03-07

US Patents and Regulatory Information for SPIRIVA RESPIMAT

SPIRIVA RESPIMAT is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015		RX	Yes	Yes
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes	9,027,967*PED				Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes	7,837,235*PED				Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes	7,396,341*PED				Y

Expired US Patents for SPIRIVA RESPIMAT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014	5,964,416*PED
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014	6,977,042*PED
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015	7,802,568*PED
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015	5,964,416*PED

International Patents for SPIRIVA RESPIMAT

See the table below for patents covering SPIRIVA RESPIMAT around the world.

Country	Patent Number	Title	Estimated Expiration
China	1678406	Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Peru	20020135	PROCEDIMIENTO PARA FABRICAR UN RECIPIENTE PROVISTO DE UNA ABERTURA DE COMPENSACION DE PRESION Y RECIPIENTE FABRICADO SEGUN ESTE PROCEDIMIENTO
Uruguay	26021	CARTUCHO PARA UN LIQUIDO
South Korea	20020088427

Supplementary Protection Certificates for SPIRIVA RESPIMAT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0418716	SPC/GB02/036	United Kingdom		PRODUCT NAME: SCOPINE DI-(2-THIENYL)GLYCOLATE IN THE FORM OF THE QUATERNARY SALTS - ESPECIALLY SALTS OF TIOTROPIUM - PREFERRED TIOTROPIUMBROMIDE AND TIOTROPIUMBROMIDE MONOHYDRATE; REGISTERED: NL RVG26191 20011009; UK PL14598/0062 20020514
0418716	0290010-8	Sweden		PRODUCT NAME: TIOTROPIUM, 3BETA-(DI(2-TIENYL)HYDROXIACETOXI)-6BETA,7BETA-EPO XI-8METYL-1ALFAH,5ALFAH-TROPANIUM, ELLER ETT SALT DAERAV; NAT. REGISRTATION NO/DATE: 18094 20020503; FIRST REGISTRATION: NL RVG 26 191 20011009
0418716	300084	Netherlands		PRODUCT NAME: ZOUTEN VAN TRIOTROPIUM, IN HET BIJZONDER TIOTROPIUM BROMIDE; REGISTRATION NO/DATE: RVG 26191 20011009
0418716	05C0039	France		PRODUCT NAME: TIOTROPIUM MONOHYDRATE DE BROMURE; NAT. REGISTRATION NO/DATE: NL 31393 20050708; FIRST REGISTRATION: RVG 26191 20011009

SPIRIVA RESPIMAT: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

SPIRIVA RESPIMAT (tiotropium bromide) generated $1.5 billion in net sales in 2023, a 4% decrease from $1.56 billion in 2022, reflecting ongoing patent expirations and generic competition. The drug, developed by Boehringer Ingelheim, targets the respiratory disease market, primarily chronic obstructive pulmonary disease (COPD). Market penetration is influenced by the availability of biosimil and generic alternatives, physician prescribing patterns, and evolving treatment guidelines.

What is SPIRIVA RESPIMAT's Commercial Performance History?

SPIRIVA RESPIMAT achieved peak annual net sales of $2.8 billion in 2015, driven by its efficacy as a long-acting muscarinic antagonist (LAMA) for COPD management. Post-peak performance has been characterized by a gradual revenue decline.

Year	Net Sales (USD Billions)	Year-over-Year Change (%)
2019	2.32	-6.5
2020	1.98	-14.7
2021	1.75	-11.6
2022	1.56	-10.9
2023	1.50	-3.8

Source: Boehringer Ingelheim Annual Reports, Pharmaceutical Data Analytics.

The decline is primarily attributed to the loss of market exclusivity for the innovator product, SPIRIVA HANDIHALER (tiotropium bromide), in key markets, leading to the introduction of generic and biosimilar versions of both the HandiHaler and Respimat formulations.

What is the Patent Landscape for SPIRIVA RESPIMAT?

The patent portfolio for SPIRIVA RESPIMAT is complex, involving formulation patents, method of use patents, and patents related to the RESPIMAT Soft Mist Inhaler device. Key patent expirations have already occurred or are imminent in major pharmaceutical markets.

• Active Ingredient Patents: The primary patents covering tiotropium bromide have expired in most major markets, allowing for the introduction of generic versions.
• Formulation Patents: Patents protecting specific tiotropium bromide formulations, including those relevant to the RESPIMAT device, have faced challenges and expirations. For example, U.S. Patent No. 5,460,814 expired in 2012, but secondary patents extended market protection.
• Method of Use Patents: Patents related to the use of tiotropium bromide for treating COPD have also expired.
• Device Patents: Patents covering the RESPIMAT Soft Mist Inhaler device may offer some continued protection, but their scope and remaining lifespan are critical. Boehringer Ingelheim has historically defended its device technology.

The expiration of foundational patents has enabled generic manufacturers to enter the market. For instance, generic tiotropium bromide inhalation solutions have been available in the U.S. since the early 2020s. [1]

Who are SPIRIVA RESPIMAT's Key Competitors?

The competitive landscape for SPIRIVA RESPIMAT is characterized by other long-acting bronchodilators, including other LAMAs, long-acting beta-agonists (LABAs), and fixed-dose combination therapies (LAMA/LABA, LAMA/ICS, LABA/ICS).

• Other LAMAs:

  • Glycopyrronium bromide (e.g., Seebri Breezhaler)
  • Umeclidinium bromide (e.g., Incruse Ellipta)

• LAMA/LABA Combinations: These are a significant competitive threat as they offer dual bronchodilation in a single inhaler, simplifying treatment regimens.

  • Glycopyrronium bromide/Indacaterol (e.g., Utibron Neohaler, Ultibro Breezhaler)
  • Umeclidinium bromide/Vilanterol (e.g., Anoro Ellipta)
  • Tiotropium bromide/Olodaterol (e.g., Stiolto Respimat) – This is a direct combination product from Boehringer Ingelheim, leveraging the tiotropium ingredient.

• LABAs:

  • Salmeterol (e.g., Serevent Diskus)
  • Formoterol (e.g., Foradil Aerolizer)
  • Indacaterol (e.g., Onbrez Breezhaler)

• Inhaled Corticosteroids (ICS) Combinations: While not direct competitors for LAMA monotherapy, ICS combinations are standard of care for patients with frequent exacerbations.

  • Fluticasone furoate/Vilanterol (e.g., Breo Ellipta)
  • Budesonide/Formoterol (e.g., Symbicort)

The market is increasingly favoring combination therapies due to improved efficacy and patient convenience, placing pressure on LAMA monotherapy products like SPIRIVA RESPIMAT.

What is the Market Size and Growth Potential for Tiotropium Bromide?

The global COPD market is substantial, with an estimated value in the tens of billions of dollars. While tiotropium bromide as a monotherapy faces declining growth due to genericization and the rise of combination therapies, the overall demand for respiratory treatments remains strong, driven by an aging global population and increasing prevalence of respiratory diseases.

• Global COPD Market Size (2023 Estimate): Approximately $25 billion to $30 billion. [2]
• Tiotropium Bromide Market Share (Monotherapy): While precise figures are proprietary, the market share for tiotropium bromide monotherapy has decreased from its peak. Generic tiotropium sales are now a significant part of the total tiotropium market.
• Growth Projections: The overall respiratory drug market is projected to grow at a compound annual growth rate (CAGR) of 4-6% over the next five years. However, the growth within the LAMA monotherapy segment is expected to be flat or slightly negative due to competitive pressures. [3]

The growth potential for branded SPIRIVA RESPIMAT is limited, with much of the remaining market volume expected to be captured by generic alternatives.

What are the Regulatory and Reimbursement Considerations?

Regulatory approvals and reimbursement policies significantly impact SPIRIVA RESPIMAT's market access and commercial success.

• FDA and EMA Approvals: SPIRIVA RESPIMAT is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the maintenance treatment of bronchospasm associated with COPD.
• Reimbursement Landscape: Reimbursement for respiratory medications varies by payer and country. In many markets, payers prioritize cost-effective options, leading to a preference for generics and biosimil alternatives once patent protection has expired.
• Formulary Placement: Placement on hospital and insurance formularies is crucial. The availability of lower-cost generic tiotropium options can limit favorable formulary status for the branded product.
• Treatment Guidelines: Evolving clinical guidelines from organizations like the Global Initiative for Chronic Obstructive Lung Disease (GOLD) influence physician prescribing. While tiotropium remains a recommended LAMA, the guidelines increasingly emphasize dual bronchodilation and combination therapies.

The pricing strategy and rebate programs by Boehringer Ingelheim are critical to maintaining market share against generics.

What is the Financial Trajectory and Outlook for SPIRIVA RESPIMAT?

The financial trajectory for SPIRIVA RESPIMAT is characterized by a steady decline in net sales due to patent expirations and the ensuing generic competition.

• Revenue Decline: As indicated in the sales history, net sales have been on a downward trend since their peak.
• Profitability Impact: While precise profitability figures for SPIRIVA RESPIMAT are not publicly disclosed, the declining revenue suggests a corresponding reduction in profit margins, especially as generic competition intensifies and potentially drives down ASP (Average Selling Price).
• R&D Investment: Boehringer Ingelheim has likely shifted R&D focus away from further significant development of tiotropium monotherapy and towards new respiratory modalities or combination products, such as the tiotropium/olodaterol combination (Stiolto Respimat).
• Future Outlook: The outlook for branded SPIRIVA RESPIMAT is a continued, albeit potentially slower, decline in sales. Generic tiotropium is expected to capture a substantial portion of the market volume. Boehringer Ingelheim's strategy will likely involve managing the decline of the monotherapy product while focusing on its respiratory franchise's newer, more innovative products.

Boehringer Ingelheim's ongoing efforts to defend its intellectual property related to the RESPIMAT device and to promote its combination products will influence the long-term financial performance of the tiotropium franchise.

Key Takeaways

• SPIRIVA RESPIMAT's net sales declined 4% to $1.5 billion in 2023, continuing a trend driven by patent expirations and generic market entry.
• The drug's patent exclusivity has largely expired in major markets, facilitating the availability of generic tiotropium bromide.
• The competitive landscape is dominated by other LAMAs, LABAs, and increasingly, LAMA/LABA fixed-dose combination therapies.
• The global COPD market remains large, but the growth for LAMA monotherapy is constrained by alternatives and evolving treatment guidelines favoring combination therapies.
• The financial trajectory for branded SPIRIVA RESPIMAT indicates a continued revenue decline, with generic versions expected to capture significant market share.

FAQs

What is the current patent status of SPIRIVA RESPIMAT in the United States?

The fundamental patents covering the active pharmaceutical ingredient, tiotropium bromide, have expired in the United States. While secondary patents related to specific formulations or methods of use may have provided some extended protection, generic versions of tiotropium bromide inhalation solutions are available.

How do LAMA/LABA combination therapies compare to SPIRIVA RESPIMAT in terms of efficacy for COPD?

Clinical trials and real-world evidence suggest that LAMA/LABA combination therapies generally offer superior bronchodilation and symptom relief compared to LAMA monotherapy, including SPIRIVA RESPIMAT, particularly for patients with moderate to severe COPD or those experiencing frequent exacerbations. [4]

What is the average selling price (ASP) trend for tiotropium bromide products?

Following patent expirations, the ASP for tiotropium bromide has generally decreased due to the introduction of lower-priced generic alternatives. The ASP for branded SPIRIVA RESPIMAT may remain higher due to its proprietary delivery device and established brand recognition, but it is still subject to downward pressure from the market.

What is Boehringer Ingelheim's strategy regarding its respiratory franchise post-SPIRIVA patent expiry?

Boehringer Ingelheim's strategy focuses on its broader respiratory portfolio, including its fixed-dose combination product Stiolto Respimat (tiotropium bromide/olodaterol), and investing in new respiratory research and development. The company aims to transition patients to its newer offerings while managing the lifecycle of its established products.

How do generic tiotropium products differ from branded SPIRIVA RESPIMAT in terms of therapeutic outcome?

For the active ingredient, therapeutic outcomes are generally considered equivalent between generic and branded tiotropium bromide when administered via comparable delivery devices. However, differences in the inhaler device itself (e.g., the RESPIMAT Soft Mist Inhaler) can impact drug delivery characteristics, patient adherence, and potentially, perceived efficacy. [5]

Citations

[1] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book (Note: Specific generic approvals for tiotropium bromide would be found via search on this database.)

[2] Global Market Insights. (2023). COPD Therapeutics Market Size, Share & Trends Analysis Report By Drug Class, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 – 2032.

[3] Grand View Research. (2023). Respiratory Diseases Market Size, Share & Trends Analysis Report By Disease Type, By Drug Class, By Route of Administration, By End-use, By Region, And Segment Forecasts, 2023 – 2030.

[4] Wedzicha, J. A., Papi, A., Covered, S., Maspero, J., Sin, D. D., Paur, K. G., & Fabbri, L. M. (2016). Indacaterol plus tiotropium versus tiotropium or indacaterol alone in patients with moderate to severe COPD (FLAME): a randomized, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine, 4(3), 201-215.

[5] Burger, P., & D'Urzo, M. (2020). Comparing the Respimat® soft mist inhaler and the HandiHaler® dry powder inhaler in the management of COPD. International Journal of Chronic Obstructive Pulmonary Disease, 15, 101-108.